Veronika Gjertsen Rypdal

Rypdal disputerer for ph.d.-graden i helsevitenskap og vil offentlig forsvare avhandlingen:

"Prediction of unfavorable outcome in Juvenile Idiopathic Arthritis (JIA) and assessment of the long-term outcomes in JIA-associated uveitis – A prospective Nordic multicenter study of JIA from childhood to adulthood."

Avhandlingen er tilgjengelig her! / The doctoral thesis is available here!

Disputasen og prøveforelesningen blir strømmet. The defense and the trial lecture will be streamed.

Prøveforelesning over oppgitt emne starter kl. 10.15 / The trial lecture starts at 10.15
Tittel/Title: “How can risk prediction models be successfully implemented in clinical practice?
Prøveforelesningen strømmes her / The trial lecture will be streamed here

Disputasen starter kl. 12.15 / The defense starts at 12.15
Disputasen strømmes her / The defense will be streamed here
De som ønsker å opponere ex auditorio kan sende e-post til leder av disputasen. 
Opponents ex auditorio should sign up to leader of defense by e-mail to:

Populærvitenskapelig sammendrag av avhandlingen/ Summary of the thesis

Juvenile idiopathic arthritis (JIA) is the most common rheumatic disease in children. The exact cause is unknown, but we know that the disease course and prognosis may improve if potent treatment is started early after onset.

In our Nordic JIA project, we used clinical information available at disease onset to develop and test models for predicting future disease course for each child. The models were valid and achieved acceptable to excellent predictive ability among Nordic and Canadian children with JIA. The models are easy to use in clinical practice and may provide decision support on when to start or intensify treatment.

Children with JIA are at risk of an inflammation in the eye called uveitis. To detect uveitis, which is usually asymptomatic, all children with JIA need regular eye doctor screening. In our Nordic JIA cohort, 1 in 5 developed uveitis and 39% of these developed sight-threatening complications within 18 years after disease onset.

Veiledere/ Supervisors:
Hovedveileder/Main supervisor:
Førsteamanuensis Ellen Berit Nordal, Institutt for klinisk medisin,Det helsevitenskapelige fakultet, UiT Norges arktiske universitet
Førsteamanuensis Geir Bertelsen, Institutt for samfunnsmedisin, Det helsevitenskapelige fakultet, UiT Norges arktiske universitet

Professor Berent Prakken, University Medical Center (UMC) Utrecht – 1. opponent
Professor Kimme Hyrich, Arthritis Research centre for Epidemiology, University of Manchester, and Kellgren Center for Rheumatology, Manchester University Hospitals  - 2. opponent
Førsteamanuensis Christen Peder Dahl, Institutt for klinisk medisin, UiT, Det helsevitenskapelige fakultet, UiT Norges arktiske universitet – leder av komité

Disputasleder/ Leader of defense:
Professor Claus Klingenberg, Institutt for klinisk medisin, Det helsevitenskapelige fakultet, UiT Norges arktiske universitet

Når: 21.05.21 kl 10.15–16.00
Hvor: Strømmes fra auditorium Cortex
Sted: Digitalt
Målgruppe: Ansatte, Studenter, Gjester / eksterne, Inviterte
Kontakt: Andrea Jennerwein
Legg i kalender